Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Leadership Evolution at Ogilvy CommonHealth Worldwide’s New Jersey-Based Specialty and Payer Agencies

PARSIPPANY, NJ–(Marketwired – Jun 24, 2015) – Ogilvy CommonHealth Worldwide (, the health behavior change specialists of Ogilvy & Mather (, and a WPP company (NASDAQ: WPPGY) (, today announced two executive-level changes within management at the organization’s headquarters in Parsippany — with the appointment of Michael Zilligen as president of both Ogilvy CommonHealth Payer […]

Read More »

Fat Is Back: New Guidelines Abandon The Upper Limit On Dietary Fat

The latest version of the Dietary Guidelines for Americans – the government-sanctioned recommendations about what we should and shouldn’t eat – will include a game-changing edit: There’s no longer going to be a recommended upper limit on total fat intake. This hasn’t gotten as much press as the other big change – that cholesterol will no longer be considered a […]

Read More »

Игровой Клуб Вулкан – Бесплатные Игровые Автоматы В Онлайн Режиме

Талантливые художники этой компании поработали над тем, чтобы создать необычный, красочный и яркий дизайн для каждого из развлечений.

Read More »

AstraZeneca loses second top executive as Vectura gets new CEO

AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura. His departure follows the exit earlier this month of Briggs Morrison, AstraZeneca’s former chief medical officer and head of late-stage drug development, who moved […]

Read More »

Via the internet wagering may just be the continued of pleasure!

Good serves up from real-time casino site website In connection with the slow bar of distinct sectors of casino internationally, the people who own the larger betting agencies began to set up distinct carry out places for persistent clientele.

Read More »

Google Genomics adds Broad Institute’s DNA analysis toolkit

Google Genomics, the cloud-based computing business that is racing to increase its share of online DNA analytics, on Wednesday began offering a cloud service version of the popular DNA analysis software from the Broad Institute, a biomedical research organization. The Google Inc research tie-up comes as academic institutions and healthcare companies are choosing between Google […]

Read More »

Study shows drug combination can treat bipolar depression

NeuroRx Inc said initial results of a small study show a combination of several drugs can reduce symptoms of depression and suicidal tendencies in patients with bipolar disorder and maintain that effect over time. The peer-reviewed study of eight patients, elements of which were published on Wednesday in the Journal of Clinical Psychiatry, showed a 50 […]

Read More »

Naloxone Continues Reversing Opioid Overdoses, Study Shows

As the medical community continues searching for ways to curb opioid-related deaths through treatment and management, the pharmaceutical industry proceeds with pushing for naloxone, a generic drug also known as Narcan – and the results are paying off. A new Morbidity and Mortality Weekly Report (MMWR) published by the Centers for Disease Control and Prevention (CDC) revealed that naloxone kits […]

Read More »

AbbVie hepatitis C cocktail succeeds in late-stage study

AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study. Viekira Pak, a combination of the drugs Viekirax and Exviera, was approved in December […]

Read More »

Alcobra’s genetic disorder drug fails in mid-stage trial

Israel-based Alcobra Ltd said its experimental drug failed in a mid-stage trial to treat Fragile X Syndrome, a type of genetic disorder that could cause autism. Alcobra said it plans to discuss trial results with the U.S. Food and Drug Administration before finalizing the design of the next study.       (Reporting by Anjali […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom